Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Return on Invested Capital (2017 - 2025)

Avalo Therapeutics' Return on Invested Capital history spans 9 years, with the latest figure at 0.84% for Q4 2025.

  • For Q4 2025, Return on Invested Capital rose 5.0% year-over-year to 0.84%; the TTM value through Dec 2025 reached 0.84%, up 5.0%, while the annual FY2025 figure was 0.68%, 30.0% up from the prior year.
  • Return on Invested Capital reached 0.84% in Q4 2025 per AVTX's latest filing, down from 0.68% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 11.67% in Q3 2022 to a low of 343.25% in Q2 2022.
  • Average Return on Invested Capital over 5 years is 18.16%, with a median of 0.86% recorded in 2024.
  • Peak YoY movement for Return on Invested Capital: tumbled -34044bps in 2022, then soared 34638bps in 2023.
  • A 5-year view of Return on Invested Capital shows it stood at 2.59% in 2021, then soared by 324bps to 5.79% in 2022, then plummeted by -143bps to 2.49% in 2023, then surged by 64bps to 0.89% in 2024, then grew by 6bps to 0.84% in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Return on Invested Capital are 0.84% (Q4 2025), 0.68% (Q3 2025), and 0.53% (Q2 2025).